Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04734197
Other study ID # C-100-001
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date January 11, 2021
Est. completion date March 25, 2022

Study information

Verified date February 2023
Source Surface Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

SURF-100 is being studied for the treatment of dry eye disease. SURF-100 is an investigational drug (which means the study drug is currently being tested) in the form of a sterile eye drop. The purpose of this research study is to see how well SURF-100 works to treat dry eye and what potential side effects there are, and to compare it with Vehicle (placebo), 0.1% mycophenolic acid (MPA) in Vehicle, 0.3% MPA in Vehicle, 0.01% betamethasone phosphate (BSP) in Vehicle, Restasis and Xiidra. This study will involve about 280-350 study participants age 18 and older at about 40 different research sites in the United States.


Recruitment information / eligibility

Status Completed
Enrollment 351
Est. completion date March 25, 2022
Est. primary completion date March 25, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Adults at least 18 years of age at the time of the Screening visit. 2. Willing and able to read, sign, and date the informed consent form (ICF) after the nature of the study has been explained and any questions have been answered, and prior to initiation of any study procedures or exams. 3. Willing and able to comply with all study procedures and attend all study visits. 4. Willing to suspend use of tear substitutes at least 72 hours prior to Visit 2 (Day 0) through Visit 7 (Day 98). 5. Best corrected visual acuity (BCVA) of 0.7 log of the minimum angle of resolution (logMAR) or better (Snellen equivalent score of 20/100 or better) in each eye at Visit 1 (Day -14 to Day 0). 6. Subject-reported history of dry eye in both eyes. 7. Meeting ALL of the following criteria in the same eye at Visit 1 (Day -14 to Day 0) and meeting ALL of the following criteria in the same eye at Visit 2 (Day 0) if Visit 2 is performed >5 days after Visit 1: 1. Minimum score of greater than or equal to 5 but less than or equal to 9 on UNC DEMS questionnaire. 2. Schirmer Tear Test (with anesthesia) equal to or less than 10 mm, but more than 1 mm. 3. TBUT: Equal to or less than 5 seconds 8. A negative urine pregnancy test if female and of childbearing potential (those who are not surgically sterilized [bilateral tubal ligation, hysterectomy, or bilateral oophorectomy] or post-menopausal [12 months after last menses] or premenarchal) and must have used adequate birth control throughout the study period (through Visit 7 [Day 98]). Adequate birth control is defined as hormonal-oral, implantable, injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with a barrier such as condom or diaphragm; intrauterine device; abstinence; or surgical sterilization of male partner. 9. Subjects with secondary Sjögren's syndrome (e.g., rheumatoid arthritis, systemic lupus erythematosus) or other autoimmune diseases (e.g., multiple sclerosis, inflammatory bowel disease) are eligible for study consideration provided the subject meets all other inclusion and exclusion criteria, AND are not in a medical state - in the opinion of the principal investigator - that could interfere with study parameters, are not taking systemic/ocular steroids, and are not immunodeficient/immunosuppressed (e.g., receiving systemic immunomodulating or immunosuppressive drugs to manage their baseline medical state). Exclusion Criteria: 1. Contraindications or known hypersensitivity to the study drug(s), including RESTASIS or XIIDRA, or their components. 2. Subjects who are employees or immediate family members of employees at the investigational site. 3. Subjects who are members of the same household. 4. Any ocular condition that, in the opinion of the investigator, may affect study parameters including, but not limited to, lid margin disorders (e.g., blepharitis including staphylococcal, demodex, or seborrheic; excessive lid laxity, floppy eyelid syndrome, ectropion, entropion), advanced conjunctivochalasis, Salzmann's nodular degeneration, and asthenopia-related conditions, allergic conjunctivitis, glaucoma, diabetic retinopathy, follicular conjunctivitis, iritis, uveitis, wet-exudative age-related macular degeneration, retinal vein occlusion, and/or active ocular inflammation. 5. Any condition that could affect trigeminal nerve function including facial or ocular Herpes Zoster/Shingle, a stroke or nerve palsy affecting the eye(s). 6. Use of any topical medication and/or antibiotics for the treatment of blepharitis or meibomian gland disease in either eye within 14 days prior to Visit 2 (Day 0). 7. Active or history of ocular herpes or any other ocular infection in either eye within the last 30 days prior to Visit 1 (Day -14 to Day 0). 8. Unwilling to avoid wearing contact lenses for 7 days prior to Randomization (Visit 2, Day 0) and for the duration of the study period (through Visit 7, Day 98). 9. Positive urine pregnancy test at Screening, nursing an infant or planning to become pregnant during the study. 10. Any blood donation or significant loss of blood within 56 days of Visit 1 (Day -14 to Day 0). 11. Any history of immunodeficiency disorder, human immunodeficiency virus (HIV), positive hepatitis B, C, or evidence of acute active hepatitis A (anti-hepatitis A virus immunoglobulin M), or organ or bone marrow transplant. 12. Any medication (oral or topical) known to cause ocular drying that is not administered as a stable dose for at least 30 days prior to Visit 1 (Day -14 to Day 0) and for the duration of the study (Visit 7, Day 98); antihistamines are not allowed at any time during the study. 13. Use of prohibited medications (topical, topical ophthalmic and/or systemic, during the appropriate pre-study washout period (see below) and during the study. Prohibited medications include topical cyclosporine or lifitegrast, use of any other ophthalmic medication (e.g., glaucoma medication, topical anti-inflammatory eye drops) for the duration of the study) NOTE: Supplements containing omega-3 are allowed if the subject has been taking said supplement for at least 3 months prior to Screening. Subjects are not allowed to begin taking supplements containing omega-3 during the study. The appropriate pre-study washout period is as follows: 1. Antihistamines (including ocular): 7 days prior to Visit 1 (Day -14 to Day 0). 2. Topical cyclosporine or lifitegrast or omega-3s within 14 days prior to Visit 1 (Day -14 to Day 0). 3. Corticosteroids or mast cell stabilizers (including ocular): 14 days prior to Visit 1 (Day -14 to Day 0). 4. Depot-corticosteroids in either eye at least 45 days prior to the first dose of study drug (Day 0) 5. All other topical ophthalmic preparations (including artificial tear substitutes other than the study drops): 72 hours prior to Visit 1 (Day -14 to Day 0). 6. Introduction of any new, nonsteroidal anti-inflammatory drugs (NSAIDs) including but not limited to topical, systemic (including sleep-aids containing NSAIDs), inhaled, or irrigation solution within 7 days prior to the first dose of study drug. Subjects who are on stable dose of NSAIDs (stable for at least 4 weeks prior to the first dose of study drug) are eligible for participation and should remain on a stable dose throughout the duration of the study (i.e., through Day 98). 7. Triamcinolone in either eye at least 90 days prior to the first dose of study drug (Day 0). 8. Inhaled, ingested, sublingual, transdermal or topical products containing marijuana, tetrahydrocannabinol (THC) or cannabidiol (CBD) at least 7 days prior to the first dose of study drug (Day 0). 9. Systemic pain relievers, analgesics (e.g., pregabalin, gabapentin, opioids) 14 days prior to the first dose of study drug (Day 0). 10. Any supplement, prescribed medication or over-the-counter product that the investigator feels may interfere with the study parameters, including homeopathic remedies, analgesics, and pain medication. 11. Oral doxycycline within 6 months of first dose of study drug (Day 0). 12. Diuretics: Within 28 days prior to Visit 1 (Day -14 to Day -1). 13. Punctal occlusion: i. Punctal cauterization: Randomization may not occur until 4 weeks following the procedure. ii. Permanent/semi-permanent punctal plugs (this includes 180-day punctal plugs): Randomization may not occur until 4 weeks following the procedure. If a punctal plug falls out during the study, it should be reinserted. iii. Temporary collagen punctal plugs: Not permitted. If subject has a history of use of temporary punctal plugs, randomization may not occur until 4 weeks since last insertion and puncta are plug-free, as determined by the investigator. 14. Any significant chronic illness that, in the opinion of the investigator, could interfere with the study parameters, including, but not limited to, severe cardiopulmonary disease, poorly controlled hypertension, and/or poorly controlled diabetes. 15. Use of any investigational product or device within 30 days prior to Visit 1 (Day -14 to Day 0) or during the study period. 16. History of LASIK or similar type of corneal refractive surgery within 12 months prior to Visit 1 (Day -14 to Day 0), and/or any other ocular surgical procedure within 12 months prior to Visit 1 (Day -14 to Day 0); or any scheduled ocular surgical procedure during the study period. 17. Use of any laser procedure for the eyes in the 30 days prior to Visit 1 (Day -14 to Day 0). 18. Known history of alcohol and/or drug abuse within the past 12 months that in the opinion of the principal investigator, may interfere with study compliance, outcome measures including safety parameters, and/or the general medical condition of the subject. 19. Subjects with dry eye secondary to scarring (such as that seen with irradiation, alkali burns, Stevens Johnson syndrome, cicatricial pemphigoid) or destruction of conjunctival goblet cells (as with vitamin A deficiency) are not eligible for the study. Subjects with incidental scars secondary to refractory surgery (i.e., LASIK surgery) that, in the opinion of the principal investigator, would not interfere with study compliance and/or outcome measures, are not excluded from the study. 20. Subjects who test positive for the COVID-19 virus within 30 days prior to Visit 1 (Day -14 to Day 0).

Study Design


Intervention

Drug:
SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate)
combination of a topical immunosuppressant and a topical corticosteroid solution
Mycophenolic Acid 0.1%
topical immunosuppressant
Mycophenolic Acid 0.3%
topical immunosuppressant
Betamethasone Sodium Phosphate 0.01%
topical corticosteroid solution
Placebo Comparator: Vehicle
topical vehicle solution
Cyclosporine 0.05% Ophthalmic Emulsion
topical ophthalmic emulsion
Lifitegrast 5% Ophthalmic Solution
topical ophthalmic solution

Locations

Country Name City State
United States Texan Eye Care, PA - Keystone Research, Ltd Austin Texas
United States Canyon City EyeCare Azusa California
United States Florida Eye Microsurgical Institute, Inc. Boynton Beach Florida
United States Hernando Eye Institute Brooksville Florida
United States Midwest Vision Research Foundation at Pepose Vision Institute Chesterfield Missouri
United States Scott & Christie and Associates, PC Cranberry Township Pennsylvania
United States Connecticut Eye Consultants, PC Danbury Connecticut
United States Cincinnati Eye Institute Edgewood Kentucky
United States The Eye Center of Northern Colorado Fort Collins Colorado
United States Physicians Protocol Greensboro North Carolina
United States Inland Eye Specialists Hemet California
United States Advanced Laser Vision & Surgical Institute Houston Texas
United States Houston Eye Associates Houston Texas
United States Bowden Eye and Associates Jacksonville Florida
United States Tauber Eye Center Kansas City Missouri
United States Jackson Eye Lake Villa Illinois
United States Tanner Clinic Layton Utah
United States Kentucky Eye Institute Lexington Kentucky
United States Total Eye Care, PA Memphis Tennessee
United States VRF Eye Specialty Group Memphis Tennessee
United States North Valley Eye Medical Group Inc. Mission Hills California
United States LoBue Laser and Eye Medical Center Murrieta California
United States West TN EyeCare dba Toyos Clinic Nashville Tennessee
United States Eye Research Foundation Newport Beach California
United States Eye Center of North Florida PA Panama City Florida
United States Cornea and Cataract Consultants of Arizona PC Phoenix Arizona
United States Alterman, Modi & Wolter Poughkeepsie New York
United States Martel Eye Medical Group Rancho Cordova California
United States Black Hills Regional Eye Institute Rapid City South Dakota
United States Rochester Ophthalmological Group, PC Rochester New York
United States Coastal Research Associates, LLC Roswell Georgia
United States Sacramento Eye Consultants, A Medical Corporation Sacramento California
United States Ophthalmology Consultants Ltd. Saint Louis Missouri
United States Tekwani Vision Center Saint Louis Missouri
United States The Eye Institute of Utah Salt Lake City Utah
United States Eye Clinics of South Texas, PA San Antonio Texas
United States R and R Eye Research, LLC San Antonio Texas
United States EyeSight Ophthalmic Services Somersworth New Hampshire
United States International Research Center Tampa Florida
United States Blue Ocean Clinical Research at The Macula Center The Villages Florida

Sponsors (1)

Lead Sponsor Collaborator
Surface Pharmaceuticals, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary UNC DEMS Score A reduction of 10% in patient-reported dry eye disease symptoms and reduction of impact of symptoms on daily life as defined by the University of North Carolina (UNC) Dry Eye Management Scale (DEMS) with SURF-100 as compared to vehicle, RESTASIS and XIIDRA. Day 84
Secondary Tear Break Up Time (TBUT) Average increase in TBUT compared to vehicle, RESTASIS and XIIDRA Day 84
Secondary Schirmer Tear Test Score Average increase in Schirmer's score test (with anesthesia) compared to vehicle, RESTASIS and XIIDRA. Day 84
See also
  Status Clinical Trial Phase
Completed NCT03216096 - Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye Disease Phase 1
Completed NCT05825599 - PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms N/A
Completed NCT04656197 - The Ocular Microbiome in Patients With Dry Eye Disease
Completed NCT05031806 - Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease Phase 1
Completed NCT03688802 - Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation Phase 2
Completed NCT05213156 - Concentration of Ofloxacin Into the Aqueous Humour of Patients With Dry Eye Disease Phase 4
Completed NCT04548427 - Study to Evaluate the Efficacy and Safety of CKD-352 Phase 3
Completed NCT06176651 - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers Phase 4
Completed NCT02254265 - Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca Phase 2/Phase 3
Completed NCT00395759 - The Visual Effect of an Investigational Artificial Tear in the Tear Layer. N/A
Completed NCT00680108 - A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution Phase 2
Recruiting NCT06064071 - Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD N/A
Completed NCT04139122 - Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease Phase 1/Phase 2
Not yet recruiting NCT06375343 - Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive® Phase 1
Completed NCT01468168 - A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye Patients Phase 2
Completed NCT01014078 - A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease Phase 4
Completed NCT00799682 - Exploratory Study Comparing Signs and Symptoms in Patients With Ocular Hypertension or Glaucoma Using Xalatan R® or Travatan Z® Phase 4
Completed NCT05082974 - Investigator Initiated Study to Assess the Efficacy of OC-01 (Varenicline) Nasal Spray on Signs and Symptoms of Dry Eye Disease Following Laser-assisted in Situ Keratomileusis (LASIK) Phase 3
Recruiting NCT06146881 - Effectiveness of Diquafosol Prophylactic Therapy to Prevent Dry Eye Disease for Cataract Surgery Patients in Indonesia Phase 2
Completed NCT03292809 - CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED) Phase 2/Phase 3